ecallantide (Kalbitor)

Indications: - treatment of acute attacks of hereditary angioedema in patients 16 years of age & older Dosage: - 30 mg (3 mL) SQ in 3 10 mg (1 mL) injections - if an attack persists, an additional dose of 30 mg may be administered within a 24 hour period Adverse effects: - most common (> 3%) - headache, nausea, diarrhea, pyrexia, nasopharyngitis. injection site reactions Mechanism of action: - plasma kallikrein inhibitor

General

enzyme inhibitor biological response modifier; immune factor; immunomodulator; biomodulator

References

- Prescriber's Letter 17(2): 2010 New Drugs Approved by the FDA in 2009 Detail-Document#: 260213 (subscription needed) http://www.prescribersletter.com